TiumBio's immuno-oncology candidate 'Tosposertip' data accepted for presentation at ASCO 2026 (The Bio) - Apr 2, 2026 - "At this year's ASCO Annual Meeting, Tiumbio will present the latest interim results from its Phase 2 clinical trial evaluating the combination of 'Tosposertib and Keytruda (pembrolizumab)' in a poster format."
P2 data • Biliary Tract Cancer • Colorectal Cancer • Squamous Cell Carcinoma of Head and Neck
|